GSK 的 bepirovirsen 在日本获得 SENKU 资格，用于治疗杜氏肌营养不良症。 GSK's bepirovirsen receives SENKU designation in Japan for Duchenne muscular dystrophy treatment.

GSK 的 bepirovirsen 已获得日本厚生劳动省的 SENKU 称号。 GSK's bepirovirsen has received the SENKU designation by Japan's Ministry of Health, Labour and Welfare. 该认定旨在加快解决未满足医疗需求的药物的开发和审批过程。 This designation is meant to accelerate the development and approval process for drugs addressing unmet medical needs. Bepirovirsen 是一种针对具有特定基因突变的杜氏肌营养不良症患者的治疗方法。 Bepirovirsen is a treatment for patients with Duchenne muscular dystrophy who have a specific genetic mutation.